&w=3840&q=100)
Investors rush to Spunweb Nonwoven IPO as subscription nears 3x; GMP at 36%
Spunweb Nonwoven IPO grey market premium (GMP) today
The favourable sentiments for the Spunweb Nonwoven IPO extended in the grey markets too, where the company's unlisted shares were commanding a solid premium on the first day of opening its public offering.
Sources tracking unofficial markets revealed that the company's unlisted shares were exchanging hands at ₹131 apiece, reflecting a grey market premium (GMP) of ₹35 per share, or nearly 36.46 per cent over the upper end of the issue price.
Spunweb Nonwoven IPO details
At the upper end, Spunweb Nonwoven seeks to raise ₹60.98 crore from the public offering. The company has already raised ₹173.1 crore from the anchor investors on the bidding concluded on Friday, July 11.
Spunweb Nonwoven IPO is being offered at a price band of ₹90-96 per share, and a lot size of 2400 shares. However, investors can bid for a minimum of 2 lots or 2,400 shares and in multiples of 1,200 shares thereof.
A retail investor would require a minimum of ₹2,30,400 to bid for 2 lots of Spunweb Nonwoven IPO.
Spunweb Nonwoven proposes to use the proceeds from the public issue to fund the working capital requirements of the company, for investment in the wholly owned subsidiary, SIPL, for funding its working capital requirements, as well as for the repayment, in full or in part, of certain borrowings availed by the company. The company also plans to use the proceeds for general corporate purposes.
MUFG Intime India (formerly Link Intime) is the registrar for the issue, while Vivro Financial Services is the sole book-running lead manager.
Spunweb Nonwoven Gases IPO timeline
Spunweb Nonwoven Gases IPO will remain open for subscription until Wednesday, July 16, 2025. Following that, the basis of allotment of Spunweb Nonwoven Gases IPO shares is expected to be finalised on Thursday, July 17, 2025, and shares will be credited to successful allottees' demat accounts on Friday, July 18, 2025.
Spunweb Nonwoven shares are set to list on the NSE SME on Monday, July 21, 2025.
About Spunweb Nonwoven
Spunweb Nonwoven, along with its wholly owned subsidiary, Spunweb India, is engaged in the business of manufacturing of polypropylene spunbond nonwoven fabrics primarily used in industries such as hygiene, healthcare, packaging, agriculture and others (including roofing & construction, industrial and home furnishing). As outlined in the Red Herring Prospectus (RHP), they are one of the largest manufacturers in the spunbond nonwoven fabric industry in India, with an installed production capacity of 32,640 MT as of FY24 (Source: CareEdge Report). Their product portfolio consists of hydrophobic nonwoven fabric, hydrophilic nonwoven fabric, super soft nonwoven fabric, UV treated fabric, antistatic nonwoven fabric, and FR treated fabric in the width of 1.6m, 2.6m and 3.2m with the range of 7 to 150 grams per square metre (GSM).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Intuitional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Anthem Biosciences IPO subscription status: Non-institutional investors (NIIs) were driving the demand for the initial public offering (IPO) of Anthem Biosciences on the final day of subscription. The participation from the qualified institutional buyers (QIBs), and retail investors was also encouraging as the public issue garnered bids for 48,76,15,180 equity shares against 4,40,70,682 on offer, resulting in an oversubscription of 11:06 times till 12:42 PM on Wednesday, July 16, showed the NSE data. Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes. Anthem Biosciences IPO grey market premium (GMP) today The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities. Anthem Biosciences IPO review Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile. Anthem Biosciences IPO details The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820. As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18. Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025. Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager. About Anthem Biosciences Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
Economic Times
an hour ago
- Economic Times
Anthem Biosciences IPO subscribed 4x on last day; Check GMP, and other key details
The initial public offering (IPO) of Anthem Biosciences has seen strong investor interest, with the issue being subscribed 4.01 times so far on Wednesday, the last day of bidding process. The IPO, which opened on July 14, 2025, is set to close today. ADVERTISEMENT In total, the IPO received bids for 17.66 crore shares against the 4.4 crore shares that were available for subscription. Among investor categories, non-institutional investors (NIIs) showed the most enthusiasm, subscribing 12.37 times their allotted portion. The retail investor segment was subscribed 2.38 times, while qualified institutional buyers (QIBs) bid for 60% of their share. Meanwhile, in the grey market — an unofficial market where IPO shares are traded before listing — Anthem Biosciences shares are trading at a premium of Rs 156. This indicates a potential listing gain of about 27%, based on the upper end of the IPO price band, which is Rs 570. The Rs 3,395 crore issue is entirely an offer for sale (OFS), with no fresh equity issuance. The IPO closes on July 16, and the company is set to be listed on both the NSE and price band for the issue is fixed at Rs 540–570 per share, with a minimum lot size of 26 shares. ADVERTISEMENT Brokerages including Anand Rathi and Canara Bank Securities have given the IPO a 'Subscribe' rating, citing Anthem's strong industry position, robust revenue visibility, and high-margin business IPO is valued at a price-to-earnings (P/E) ratio of 71x based on FY25 earnings, broadly in line with peers such as Syngene (P/E ~51) and Divi's Labs (P/E 83). While the valuation is on the higher side, analysts believe it is justified by the company's scale, technological edge, and consistent profitability. ADVERTISEMENT With its differentiated offering in the high-growth CRDMO (Contract Research, Development, and Manufacturing Organisation) segment, Anthem presents a compelling long-term growth opportunity, analysts said. Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics). ADVERTISEMENT Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which make up a large portion of its client base. Since inception, the company has served over 675 clients and completed more than 8,000 FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is now expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
an hour ago
- Time of India
Anthem Biosciences IPO subscribed 4x on last day; Check GMP, and other key details
The initial public offering (IPO) of Anthem Biosciences has seen strong investor interest, with the issue being subscribed 4.01 times so far on Wednesday, the last day of bidding process. The IPO, which opened on July 14, 2025, is set to close today. In total, the IPO received bids for 17.66 crore shares against the 4.4 crore shares that were available for subscription. Among investor categories, non-institutional investors (NIIs) showed the most enthusiasm, subscribing 12.37 times their allotted portion. The retail investor segment was subscribed 2.38 times, while qualified institutional buyers (QIBs) bid for 60% of their share. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo Meanwhile, in the grey market — an unofficial market where IPO shares are traded before listing — Anthem Biosciences shares are trading at a premium of Rs 156. This indicates a potential listing gain of about 27%, based on the upper end of the IPO price band, which is Rs 570. The Rs 3,395 crore issue is entirely an offer for sale (OFS), with no fresh equity issuance. The IPO closes on July 16, and the company is set to be listed on both the NSE and BSE. The price band for the issue is fixed at Rs 540–570 per share, with a minimum lot size of 26 shares. Live Events Should You Subscribe? Brokerages including Anand Rathi and Canara Bank Securities have given the IPO a 'Subscribe' rating, citing Anthem's strong industry position, robust revenue visibility, and high-margin business model. The IPO is valued at a price-to-earnings (P/E) ratio of 71x based on FY25 earnings, broadly in line with peers such as Syngene (P/E ~51) and Divi's Labs (P/E 83). While the valuation is on the higher side, analysts believe it is justified by the company's scale, technological edge, and consistent profitability. With its differentiated offering in the high-growth CRDMO (Contract Research, Development, and Manufacturing Organisation) segment, Anthem presents a compelling long-term growth opportunity, analysts said. About Anthem Biosciences Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics). Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which make up a large portion of its client base. Since inception, the company has served over 675 clients and completed more than 8,000 projects. In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 crore. Its facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is now expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
